Reuters logo
BRIEF-Genmab and Seattle Genetics to start Phase II study of tisotumab vedotin
October 10, 2017 / 10:34 AM / 9 days ago

BRIEF-Genmab and Seattle Genetics to start Phase II study of tisotumab vedotin

Oct 10 (Reuters) - Genmab A/S

* Genmab and Seattle Genetics to initiate new study of novel antibody-drug conjugate tisotumab vedotin in cervical cancer

* Genmab - ‍companies plan to start enrolling patients by first half of 2018​

* Genmab - ‍co, Seattle Genetics to start phase II study of tisotumab vedotin in patients with recurrent and/or metastatic cervical cancer​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below